Molecular Landscape in Ovarian Clear Cell Carcinoma
暂无分享,去创建一个
[1] T. Kohno,et al. Precision medicine for ovarian clear cell carcinoma based on gene alterations , 2020, International Journal of Clinical Oncology.
[2] A. Kawabata,et al. Rethinking of treatment strategies and clinical management in ovarian clear cell carcinoma , 2020, International Journal of Clinical Oncology.
[3] R. Natrajan,et al. Translational genomics of ovarian clear cell carcinoma. , 2019, Seminars in cancer biology.
[4] Mariko Sasaki,et al. Therapeutic preferability of gemcitabine for ARID1A-deficient ovarian clear cell carcinoma. , 2019, Gynecologic oncology.
[5] T. Fukumoto,et al. HDAC6 inhibition synergizes with anti-PD-L1 therapy in ARID1A-inactivated ovarian cancer. , 2019, Cancer research.
[6] D. Provencher,et al. Antitumor Activity and Safety of Pembrolizumab in Patients with Advanced Recurrent Ovarian Cancer: Results from the Phase 2 KEYNOTE-100 Study. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] H. Tsuda,et al. The first Japanese nationwide multicenter study of BRCA mutation testing in ovarian cancer: CHARacterizing the cross-sectionaL approach to Ovarian cancer geneTic TEsting of BRCA (CHARLOTTE) , 2019, International Journal of Gynecological Cancer.
[8] Dale W. Garsed,et al. Survival Following Chemotherapy in Ovarian Clear Cell Carcinoma Is Not Associated with Pathological Misclassification of Tumor Histotype , 2019, Clinical Cancer Research.
[9] K. Hasegawa,et al. Clinicopathological correlation of ARID1A status with HDAC6 and its related factors in ovarian clear cell carcinoma , 2019, Scientific Reports.
[10] Mariko Sasaki,et al. Targeting the Vulnerability of Glutathione Metabolism in ARID1A-Deficient Cancers. , 2019, Cancer cell.
[11] K. Oda,et al. Genomics to immunotherapy of ovarian clear cell carcinoma: Unique opportunities for management. , 2018, Gynecologic oncology.
[12] A. Tinker,et al. A Clinical and Molecular Phase II Trial of Oral ENMD-2076 in Ovarian Clear Cell Carcinoma (OCCC): A Study of the Princess Margaret Phase II Consortium , 2018, Clinical Cancer Research.
[13] D. Gershenson,et al. Phase II study of single-agent cabozantinib in patients with recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer (NRG-GY001). , 2018, Gynecologic oncology.
[14] G. Mills,et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade , 2018, Nature Medicine.
[15] Yi Kan Wang,et al. Clear cell carcinomas of the ovary and kidney: clarity through genomics , 2018, The Journal of pathology.
[16] J. Yasuda,et al. Identification of somatic genetic alterations in ovarian clear cell carcinoma with next generation sequencing , 2018, Genes, chromosomes & cancer.
[17] H. Chung,et al. Genomic landscape of ovarian clear cell carcinoma via whole exome sequencing. , 2017, Gynecologic oncology.
[18] Y. Okuno,et al. Exome Sequencing Landscape Analysis in Ovarian Clear Cell Carcinoma Shed Light on Key Chromosomal Regions and Mutation Gene Networks. , 2017, The American journal of pathology.
[19] A. Kawabata,et al. Prognostic impact of interleukin-6 expression in stage I ovarian clear cell carcinoma. , 2017, Gynecologic Oncology.
[20] M. Stoler,et al. Mismatch repair status and PD-L1 expression in clear cell carcinomas of the ovary and endometrium , 2017, Modern Pathology.
[21] H. Watari,et al. Whole-genome sequencing revealed novel prognostic biomarkers and promising targets for therapy of ovarian clear cell carcinoma , 2017, British Journal of Cancer.
[22] Kathleen R. Cho,et al. ARID1A-mutated ovarian cancers depend on HDAC6 activity , 2017, Nature Cell Biology.
[23] Ali Bashashati,et al. Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes , 2017, Nature Genetics.
[24] J. Elvin,et al. Comprehensive genomic profiling (CGP) of ovarian clear cell carcinomas (OCCC) identifies clinically relevant genomic alterations (CRGA) and targeted therapy options , 2017, Gynecologic oncology reports.
[25] Lauren L. Ritterhouse,et al. Clear cell ovarian cancers with microsatellite instability: A unique subset of ovarian cancers with increased tumor-infiltrating lymphocytes and PD-1/PD-L1 expression , 2017, Oncoimmunology.
[26] A. Kawabata,et al. Update on rare epithelial ovarian cancers: based on the Rare Ovarian Tumors Young Investigator Conference , 2017, Journal of gynecologic oncology.
[27] Samuel E. Jones,et al. ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A , 2016, Nature Communications.
[28] A. Okamoto,et al. Randomized Phase III Trial of Irinotecan Plus Cisplatin Compared With Paclitaxel Plus Carboplatin As First-Line Chemotherapy for Ovarian Clear Cell Carcinoma: JGOG3017/GCIG Trial. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] James T. Webber,et al. Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib , 2016, Molecular Cancer Therapeutics.
[30] N. Yanaihara,et al. Antitumor effects of interleukin‐6 (IL‐6)/interleukin‐6 receptor (IL‐6R) signaling pathway inhibition in clear cell carcinoma of the ovary , 2016, Molecular carcinogenesis.
[31] E. Oliva,et al. Mismatch Repair Protein Expression in Clear Cell Carcinoma of the Ovary: Incidence and Morphologic Associations in 109 Cases , 2016, The American journal of surgical pathology.
[32] S. Mabuchi,et al. Clear cell carcinoma of the ovary: molecular insights and future therapeutic perspectives , 2016, Journal of gynecologic oncology.
[33] A. Iasonos,et al. Ovarian clear cell carcinoma, outcomes by stage: the MSK experience. , 2015, Gynecologic oncology.
[34] K. Yamaguchi,et al. Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] Wei Zhang,et al. ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors. , 2015, Cancer discovery.
[36] H. Aburatani,et al. Integrated Copy Number and Expression Analysis Identifies Profiles of Whole-Arm Chromosomal Alterations and Subgroups with Favorable Outcome in Ovarian Clear Cell Carcinomas , 2015, PloS one.
[37] N. Yanaihara,et al. Profiling of actionable gene alterations in ovarian cancer by targeted deep sequencing. , 2015, International journal of oncology.
[38] B. Monk,et al. A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254). , 2015, Gynecologic oncology.
[39] Benjamin G. Bitler,et al. Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers , 2015, Nature Medicine.
[40] N. Yanaihara,et al. Somatic Copy Number Alterations Associated with Japanese or Endometriosis in Ovarian Clear Cell Adenocarcinoma , 2015, PloS one.
[41] S. Murphy,et al. Hepatocyte nuclear factor‐1β (HNF‐1β) promotes glucose uptake and glycolytic activity in ovarian clear cell carcinoma , 2015, Molecular carcinogenesis.
[42] Jeffrey S. Damrauer,et al. Coexistent ARID1A-PIK3CA mutations promote ovarian clear-cell tumorigenesis through pro-tumorigenic inflammatory cytokine signaling , 2014, Nature Communications.
[43] H. Ahn,et al. Lynch Syndrome in patients with clear cell and endometrioid cancers of the ovary. , 2014, Gynecologic oncology.
[44] N. Yanaihara,et al. Impact of Surgical Staging in Stage I Clear Cell Adenocarcinoma of the Ovary , 2014, International Journal of Gynecologic Cancer.
[45] Y. Yatabe,et al. Met Is the Most Frequently Amplified Gene in Endometriosis-Associated Ovarian Clear Cell Adenocarcinoma and Correlates with Worsened Prognosis , 2013, PloS one.
[46] N. Yanaihara,et al. Cytokine gene expression signature in ovarian clear cell carcinoma. , 2012, International journal of oncology.
[47] J. George,et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[48] N. Yanaihara,et al. Hypoxia promotes glycogen synthesis and accumulation in human ovarian clear cell carcinoma. , 2012, International journal of oncology.
[49] Naveena Singh,et al. Interleukin-6 as a Therapeutic Target in Human Ovarian Cancer , 2011, Clinical Cancer Research.
[50] A. Ashworth,et al. Genomic Analysis Reveals the Molecular Heterogeneity of Ovarian Clear Cell Carcinomas , 2011, Clinical Cancer Research.
[51] Kylie L. Gorringe,et al. IL6-STAT3-HIF Signaling and Therapeutic Response to the Angiogenesis Inhibitor Sunitinib in Ovarian Clear Cell Cancer , 2011, Clinical Cancer Research.
[52] Richard A. Moore,et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. , 2010, The New England journal of medicine.
[53] Tian-Li Wang,et al. Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma , 2010, Science.
[54] R. Burger,et al. Vascular Endothelial Growth Factor Is a Promising Therapeutic Target for the Treatment of Clear Cell Carcinoma of the Ovary , 2010, Molecular Cancer Therapeutics.
[55] S. Murphy,et al. Identification of an ovarian clear cell carcinoma gene signature that reflects inherent disease biology and the carcinogenic processes , 2010, Oncogene.
[56] I. Shih,et al. DNA Copy Numbers Profiles in Affinity-Purified Ovarian Clear Cell Carcinoma , 2010, Clinical Cancer Research.
[57] J. Testa,et al. mTOR Is a Promising Therapeutic Target Both in Cisplatin-Sensitive and Cisplatin-Resistant Clear Cell Carcinoma of the Ovary , 2009, Clinical Cancer Research.
[58] Marketa Zvelebil,et al. PPM1D Is a Potential Therapeutic Target in Ovarian Clear Cell Carcinomas , 2009, Clinical Cancer Research.
[59] J. Chan,et al. Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers. , 2008, Gynecologic oncology.
[60] J. Kigawa,et al. Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging , 2006, British Journal of Cancer.
[61] R. Broaddus,et al. Microsatellite instability and alteration of the expression of hMLH1 and hMSH2 in ovarian clear cell carcinoma. , 2004, Human pathology.
[62] N. Matsumura,et al. Metabolic alterations caused by HNF1β expression in ovarian clear cell carcinoma contribute to cell survival. , 2015, Oncotarget.